Ocugen Founder-CEO Musunuri on mutation-agnostic gene therapy and COVID-19 vaccine plans

Citeline Podcasts - A podcast by Citeline

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

Ocugen’s founder and CEO Shankar Musunuri speaks to Scrip about his company’s mutation-agnostic gene therapy candidate OCU-400, a commercial agreement with CanSino Biologics and plans for a bridging study of partner Bharat Biotech’s COVID-19 vaccine Covaxin post a US FDA clinical hold.

Visit the podcast's native language site